A Phase 2 Open-Label Multicenter Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma Who Have Previously Received Anti-PD-[L]1 Therapy - ARTISTRY-6

Brief description of study

This is a Phase 2, global, multicenter, open-label, cohort study designed to evaluate the antitumor activity, safety and tolerability, HRQoL, PK, and pharmacodynamics of ALKS 4230 given as monotherapy in patients with unresectable and/or metastatic melanoma following prior anti-PD-[L]1 therapy with or without anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) therapy. Patients will be enrolled into one of the following cohorts based on the patient’s specific tumor type: ? Advanced cutaneous melanoma (Cohort 1) ? Advanced mucosal melanoma (Cohort 2) Cohort 1: Patients in the advanced cutaneous melanoma cohort will receive treatment at the recommended Phase 2 dose (RP2D) and dosing schedule (either every 7 or 21 days [q7d or q21d]) of subcutaneous (SC) ALKS 4230 as identified in the Phase 1/2 ARTISTRY-2 study (ALKS 4230-001). Cohort 2: Patients in the advanced mucosal melanoma cohort will receive intravenous (IV) ALKS 4230 at the RP2D and dosing schedule as identified in the Phase 1/2 ARTISTRY-1 study (ALK4230-A101) as follows: ? Cycle 1: 6 µg/kg/day for 5 consecutive days followed by 9 days off treatment, for a total of 14 days for the treatment cycle ? Cycle 2 and all subsequent cycles: 6 µg/kg/day for 5 consecutive days followed by 16 days off treatment, for a total of 21 days each treatment cycle. Across both cohorts, patients should continue receiving ALKS 4230 for as long as they are experiencing disease control and/or immune disease control and are tolerating treatment well, or until any other criteria for treatment discontinuation are met.


Clinical Study Identifier: s20-01300
ClinicalTrials.gov Identifier: NCT04830124
Principal Investigator: Maya Dimitrova.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.